» Articles » PMID: 36831507

Sensitive Detection of Cell-Free Tumour DNA Using Optimised Targeted Sequencing Can Predict Prognosis in Gastro-Oesophageal Cancer

Abstract

In this longitudinal study, cell-free tumour DNA (a liquid biopsy) from plasma was explored as a prognostic biomarker for gastro-oesophageal cancer. Both tumour-informed and tumour-agnostic approaches for plasma variant filtering were evaluated in 47 participants. This was possible through sequencing of DNA from tissue biopsies from all participants and cell-free DNA from plasma sampled before and after surgery (n = 42), as well as DNA from white blood cells (n = 21) using a custom gene panel with and without unique molecular identifiers (UMIs). A subset of the plasma samples (n = 12) was also assayed with targeted droplet digital PCR (ddPCR). In 17/31 (55%) diagnostic plasma samples, tissue-verified cancer-associated variants could be detected by the gene panel. In the tumour-agnostic approach, 26 participants (59%) had cancer-associated variants, and UMIs were necessary to filter the true variants from the technical artefacts. Additionally, clonal haematopoietic variants could be excluded using the matched white blood cells or follow-up plasma samples. ddPCR detected its targets in 10/12 (83%) and provided an ultra-sensitive method for follow-up. Detectable cancer-associated variants in plasma correlated to a shorter overall survival and shorter time to progression, with a significant correlation for the tumour-informed approaches. In summary, liquid biopsy gene panel sequencing using a tumour-agnostic approach can be applied to all patients regardless of the presence of a tissue biopsy, although this requires UMIs and the exclusion of clonal haematopoietic variants. However, if sequencing data from tumour biopsies are available, a tumour-informed approach improves the value of cell-free tumour DNA as a negative prognostic biomarker in gastro-oesophageal cancer patients.

Citing Articles

Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies.

Mahmood U, Muhamad Faizul E, Howlett S, Amin Z, Hochhauser D, Shiu K Cancers (Basel). 2024; 16(4).

PMID: 38398088 PMC: 10886944. DOI: 10.3390/cancers16040697.


An update of clinical value of circulating tumor DNA in esophageal cancer: a systematic review and meta-analysis.

Zhang Y, Du H, Wang N, Wang L, Huang Y BMC Cancer. 2024; 24(1):129.

PMID: 38267901 PMC: 10809487. DOI: 10.1186/s12885-024-11879-6.


Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.

Mu N, Jylha C, Axelsson T, Syden F, Brehmer M, Tham E World J Urol. 2023; 41(12):3421-3427.

PMID: 37721600 PMC: 10693512. DOI: 10.1007/s00345-023-04583-w.


Liquid Biopsy in Gastrointestinal Cancers: How Close Are We to Reaching the Clinic?.

Earl J, Kataki A, Smolkova B Cancers (Basel). 2023; 15(10).

PMID: 37345168 PMC: 10216095. DOI: 10.3390/cancers15102831.


Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study.

Haider Z, Wasterlid T, Spangberg L, Rabbani L, Jylha C, Thorvaldsdottir B Front Oncol. 2023; 13:1176698.

PMID: 37333831 PMC: 10272573. DOI: 10.3389/fonc.2023.1176698.

References
1.
Slagter A, Vollebergh M, Caspers I, van Sandick J, Sikorska K, Lind P . Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial. Gastric Cancer. 2021; 25(2):401-410. PMC: 8882113. DOI: 10.1007/s10120-021-01258-6. View

2.
Azad T, Chaudhuri A, Fang P, Qiao Y, Esfahani M, Chabon J . Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology. 2019; 158(3):494-505.e6. PMC: 7010551. DOI: 10.1053/j.gastro.2019.10.039. View

3.
Nakano K, Koh Y, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M . Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma. Cancer Sci. 2022; 113(5):1830-1842. PMC: 9128184. DOI: 10.1111/cas.15334. View

4.
Karczewski K, Francioli L, Tiao G, Cummings B, Alfoldi J, Wang Q . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443. PMC: 7334197. DOI: 10.1038/s41586-020-2308-7. View

5.
Salk J, Schmitt M, Loeb L . Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018; 19(5):269-285. PMC: 6485430. DOI: 10.1038/nrg.2017.117. View